NeoStem, Inc. (NBS), a leading-edge healthcare company that intends to capitalize on existing stem cell applications, has released an investor video detailing the promise of adult stem cells.
Currently, clinical trials are underway to treat many of the world’s most intractable diseases through stem cell therapy. In fact, this industry is so prevalent that analysts predict that the adult stem cell industry will generate approximately $8.5 billion in revenue by 2016.
Robin Smith, MD, MBA, Chief Executive Officer of NeoStem, also details why the Company’s services should play a key role as the field of Regenerative Medicine fulfills the promise that many medical and scientific professionals anticipate.
“In the United States alone, there are nearly 700 ongoing studies currently underway to develop medical therapies based on adult stem cells, with nearly 200 of them focused on autologous applications,” said Dr. Smith during the video. “NeoStem believes there will be an overall growth in the adult stem cell industry, and it will be well positioned to capitalize on this growth.”
To view “The Promise of Stem Cells” investor video, please visit http://www.trilogy-capital.com/tcp/neostem
Let us hear your thoughts below:
